HERCULES, Calif. - Bio-Rad Laboratories, Inc. (NYSE:BIO) reported fourth-quarter results that fell short of analyst expectations, sending shares down 4% in after-hours trading Thursday.
As Rocket Lab successfully scales, its business model should lead to a faster-than-expected breakeven during FY 2026. Click ...
As of Thursday morning, IDEXX Laboratories shares are down by 0.49%, with a current price of $455.12. This implies that Erickson's 1,544 shares have a value of $597,944.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback